888409-27-6

Upstream product

• 50850-93-6 ethyl 2-aminobenzothiazole-6-carboxylate 
• 874-60-2 4-methyl-benzoyl chloride 
• 94-09-7 p-aminoethylbenzoate 

Downstream Products

• 1428621-57-1 2-(4-methylbenzamido)benzo[d]thiazol-6-carboxylic acid 
• 1428621-60-6 2-(4-methylbenzamido)-N-phenylbenzo[d]thiazol-6-carboxamide 
• 1428621-61-7 methyl 2-[2-(4-methylbenzoylimino)-6-(phenylcarbamoyl)benzo[d]thiazol-3(2H)-yl]butanoate 
• 1428621-57-1 2-((4-methylbenzoyl)imino)-2,3-dihydrobenzo[d]thiazol-6-carboxylic acid 
• 1428621-83-3 N-(6-(azetidin-1-carbonyl)benzo[d]thiazol-2(3H)-ylidene)-4-methylbenzamide 
• 1428621-82-2 2-(6-(azetidin-1-carbonyl)-2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)butanoic acid 
• 1428621-84-4 methyl 2-(6-(azetidin-1-carbonyl)-2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)butanoate 
• 1428621-97-9 N-methyl-2-(4-methylbenzamido)benzo[d]thiazol-6-carboxamide 
• 1428621-98-0 methyl 2-(2-(4-methylbenzoyl)imino)-6-(methylcarbamoyl-3(2H)-yl)butanoate 
• 1428621-96-8 2-(2-(4-methylbenzoylimino)-6-(methylcarbamoyl)benzo[d]thiazol-3(2H)-yl)butanoic acid 

Relevant academic research and scientific papers

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.